Japanese Catheter Ablation Registry

NCT ID: NCT03729232

Last Updated: 2023-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-01

Study Completion Date

2030-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Japanese Cather Ablation (J-AB) Registry is a voluntary nationwide registry, performed by Japanese Heart Rhythm Society, collaborated with the National Cerebral and Cardiovascular Center. The objectives of this registry are to observe and describe developments in the catheter ablation treatment of arrhythmia in Japan and to provide reliable information on the type of activity performed and the facilities available in Japanese arrhythmia units.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Japanese Cather Ablation (J-AB) Registry is a nationwide, multicenter, observational registry, performed by Japanese Heart Rhythm Society, collaborated with National Cerebral and Cardiovascular Center.

This study is a voluntary nationwide registry and data are collected prospectively using a Research Electronic Data Capture (REDCap) system. Detailed data collection including antiarrhythmic medication is also performed at every September. The acute success rate at discharge and the complications associated with ablation procedure will be collected in all cases. Major bleeding events are defined according to Bleeding Academic Research Consortium criteria. Based on the provided information, the annual incidence and predictive factors for outcome will be investigated by the event assessment committee.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Catheter Ablation Cardiac Arrhythmias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients treated with catheter ablation in Japan

Exclusion Criteria

* Patients who refused to consent
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cerebral and Cardiovascular Center, Japan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kengo Kusano

Director of Cardiovascular Medicine, National Cerebral and Cardiovascular Center

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Teiichi Yamane, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

The Jikei University School of Medicine

Kengo Kusano, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

National Cerebral and Cardiovascular Center, Japan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Cerebral and Cardiovascular Center

Suita, Osaka, Japan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Japan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kengo Kusano, MD, PhD

Role: CONTACT

+81-6-6170-1070

Misa Takegami, PhD, MPH

Role: CONTACT

+81-6-6170-1070

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kengo Kusano, MD, PhD

Role: primary

+81-6-6170-1070

Misa Takegami, PhD, MPH

Role: backup

+81-6-6170-1070

References

Explore related publications, articles, or registry entries linked to this study.

Matsuda Y, Masuda M, Kanaoka K, Mano T, Inoue K, Yamashita S, Iwasaki YK, Nakamura K, Nagashima K, Miyamoto K, Satomi K, Takatsuki S, Kusano K, Yamane T, Shimizu W. Real-World Outcomes of Repeat Ablation Strategies for Atrial Fibrillation: Insights From the Japanese Catheter Ablation Registry. J Arrhythm. 2025 Sep 22;41(5):e70200. doi: 10.1002/joa3.70200. eCollection 2025 Oct.

Reference Type DERIVED
PMID: 40995616 (View on PubMed)

Goto K, Miyazaki S, Tonegawa-Kuji R, Kanaoka K, Yamashita S, Sasano T, Iwanaga Y, Nakai M, Inoue K, Iwasaki YK, Nagashima K, Nakamura K, Masuda M, Miyamaoto K, Satomi K, Takatsuki S, Kusano K, Yamane T, Shimizu W. Efficacy and Safety of Second Sessions of Catheter Ablation for Idiopathic Premature Ventricular Contractions: From the Nationwide Japan Catheter Ablation Registry. J Arrhythm. 2025 Aug 25;41(4):e70181. doi: 10.1002/joa3.70181. eCollection 2025 Aug.

Reference Type DERIVED
PMID: 40861252 (View on PubMed)

Oikawa J, Fukaya H, Kanaoka K, Niwano S, Miyamoto K, Iwanaga Y, Iwasaki YK, Nagashima K, Masuda M, Yamashita S, Nakamura K, Satomi K, Takatsuki S, Inoue K, Kusano K, Yamane T, Tada H, Shimizu W. Efficacy and safety of catheter ablation for paroxysmal atrial fibrillation: A comparison of first-line vs second-line therapy. Heart Rhythm. 2025 Jul 24:S1547-5271(25)02711-0. doi: 10.1016/j.hrthm.2025.07.030. Online ahead of print.

Reference Type DERIVED
PMID: 40714332 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UMIN000028288

Identifier Type: OTHER

Identifier Source: secondary_id

M28-114

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.